Here, we describe the first reported case of metastatic <i>BRAF</i> V600E-mutated lung adenocarcinoma that responded to dabrafenib and trametinib, and subsequently developed treatment-associated HLH-like hyperinflammatory syndrome. This evidence concerns the gene BRAF and lung adenocarcinoma.